West Pharma (WST) Tops Q4 EPS by 20c, provides guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $341.20 -0.42%
EPS Growth %: +11.7%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: +11.7%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.20 better than the analyst estimate of $1.84. Revenue for the quarter came in at $805 million versus the consensus estimate of $796.25 million.
GUIDANCE:
West Pharma sees FY2026 EPS of $7.85-$8.20, versus the consensus of $7.76.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Copart (CPRT) call put ratio 1.8 calls 1 put a share price up 3.9%
- PVH Corp. (PVH) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY27 EPS Guidance
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
